Liposomal interferon-beta: sustained release treatment of simian varicella virus infection in monkeys.
Liposomal formulations (distearoylphosphatidylcholine:dipalmitoylphosphatidylglycerol, 9:1) of recombinant human interferon-beta ser17 (IFN-beta), administered im to African green monkeys at doses of 10(7) units/kg on days 1 and 6 after infection with simian varicella virus, resulted in partial protection of the monkeys from viral infection. Aqueous interferon administered under the same dosing regimen was ineffective. When given at 10(6) units/kg per dose twice daily for 10 d, however, it was highly effective in reducing viremia and rash. The antiviral efficacy obtained with the liposomal IFN-beta formulation given in two injections 5 d apart was thus significantly more efficacious than aqueous IFN-beta given in the same dosing regimen. However, it was not as efficacious as repeated, twice-daily injections of aqueous IFN-beta. Thus, im-injected liposomal IFN-beta, which results in sustained release of the IFN-beta from the injection site, exerts antiviral efficacy in a primate model superior to that obtained with the identical dosing regimen of aqueous IFN-beta.